Evidence map›Paper›PMID 22057117›Full record

ArticleJournal of molecular evolution2011

Evolution of the TOR pathway.

Teunis J P van Dam, Fried J T Zwartkruis, Johannes L Bos, Berend Snel

Abstract read
In one paragraph

Article in Journal of molecular evolution, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Target of Rapamycin Regulates Photosynthesis and Cell Growth inInternational journal of molecular sciences · 2022
    Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Teunis J P van DamTheoretical Biology and Bioinformatics, Department of Biology, Science Faculty, Utrecht University, Padualaan 8, Utrecht, The Netherlands. Teunis.J.P.vanDam@gmail.com
Fried J T Zwartkruis
Johannes L Bos
Berend Snel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TOR kinase is a major regulator of growth in eukaryotes. Many components of the TOR pathway are implicated in cancer and metabolic diseases in humans. Analysis of the evolution of TOR and its pathway may provide fundamental insight into the evolution of growth regulation in eukaryotes and provide a practical framework on which experimental evidence can be compared between species. Here we performed phylogenetic analyses on the components of the TOR pathway and determined their point of invention. We find that the two TOR complexes and a large part of the TOR pathway originated before the Last Eukaryotic Common Ancestor and form a core to which new inputs have been added during animal evolution. In addition, we provide insight into how duplications and sub-functionalization of the S6K, RSK, SGK and PKB kinases shaped the complexity of the TOR pathway. In yeast we identify novel AGC kinases that are orthologous to the S6 kinase. These results demonstrate how a vital signaling pathway can be both highly conserved and flexible in eukaryotes.

Indexed as

Evolution, MolecularAmino Acid SequenceAnimalsConserved SequenceFungal ProteinsGene DuplicationGene Expression RegulationGene Regulatory NetworksHumansModels, GeneticMultiprotein ComplexesPhylogenyProtozoan ProteinsSequence Homology, Amino AcidSignal TransductionTOR Serine-Threonine KinasesFungal ProteinsMultiprotein ComplexesProtozoan ProteinsTOR Serine-Threonine KinasesTranscription Factors

Identifiers

PMID22057117
PMCPMC3236823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.